Why Forte Biosciences, Inc.’s (FBRX) Stock Is Up 39.59%
As of Monday, July 27, Forte Biosciences, Inc.’s FBRX share price has surged by 39.59%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Commentary & Analysis
Why Forte Biosciences, Inc.’s (FBRX) Stock Is Up 39.55%
As of Monday, July 27, Forte Biosciences, Inc.’s FBRX share price has surged by 39.55%, which has investors questioning if this is right time to sell.Tudor Pop
Why Forte Biosciences, Inc.’s (FBRX) Stock Is Up 6.97%
As of Tuesday, July 21, Forte Biosciences, Inc.’s FBRX share price has surged by 6.97%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Forte Biosciences, Inc.’s (FBRX) Stock Is Down 5.38%
As of Monday, July 13, Forte Biosciences, Inc.’s FBRX share price has dipped by 5.38%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Forte Biosciences, Inc.’s (FBRX) Stock Is Up 7.77%
As of Friday, July 10, Forte Biosciences, Inc.’s FBRX share price has surged by 7.77%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | FBRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,936.5 | $286.3 | 53% |
|
| Shares Out (Mil) | 23.8 | 54.2 | 33% |
|
| Institutional Ownership | 97.4% | 92.8% | 74% |
|
| Float (Mil) | 18.7 | 39.7 | 28% |
|
| Beta | 2.64 | 0.94 | 97% |
|
| Avg Daily Volume (000s) | 1,755 | 534 | 80% |
|
| Price Change (52-week) |
554.4% | 58.7% | 100% |
|
| Growth | FBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (8.3%) | (10.1%) | 31% |
|
| EPS (5yr) | 50.5% | 16.0% | 93 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (53.8%) | (15.6%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 5 | 5 | |
| Current EPS | ($0.781) | ($3.933) | ($3.945) | |
| Month Ago EPS | ($1.005) | ($4.010) | ($4.142) | |
| # Rev Up | 3 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($1.005) | ($4.010) | ($4.142) | |
| Year/Year Chg | (20.4%) | (16.6%) | (44.6%) | |
| Financials | FBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($88) | ($43) | 12% |
|
| EPS (TTM) | ($4.545) | ($1.400) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($72) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $1,737 | $160 | 47% |
|
| Valuation | FBRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.22 | 2.77 | 90% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | FBRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (56.1%) | (47.3%) | 10% |
|
| ROE | (62.3%) | (55.0%) | 13% |
|
| Liabilities to Assets | 10.7% | 29.6% | 6% |
|
| F-Score | 2 | 2 | 7% |
|
Forte Biosciences, Inc. did not pass any screens on 8/20/2026.
